(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Step by step instructions to Get the Best Vehicle Rent Arrangement: Insider Tips and Systems - 2Most loved Public Dish: Which One Addresses Its Nation Best?
- 3German Easter peace marches draw tens of thousands
- 45 Side interests That Work on Psychological wellness
- 5Instructions to Warmly greet Certainty and Appeal
- Instructions to Pick the Right Gold Speculation Procedure: Exploring the Market
- Does physics say that free will doesn't exist?
- Taylor Frankie Paul's domestic violence case is fueling discussions about DARVO. Experts say terms like this shouldn't be used lightly.
- Bolsonaro says hallucinatory effects of meds made him tamper with ankle tag
- Pleasant Cycle Courses All over the Planet
- Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
- Whale stranded off Germany for days found stuck again
- Alice Wong, founder of the Disability Visibility Project, dies at 51
- Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
